Istradefylline

IUPAC: (E) -1,3- Diethyl -8 -(3,4- dimethoxystyryl ) - 7 -methyl- 3 ,7- dihydro-1H -purine -2 ,6- dione

Psychotropic

Adenosine receptor antagonist

Template: Infobox chemical / molecular formula search available

Istradefyllin is a drug selected from the group of the psychopharmaceuticals which is to be used for the treatment of Parkinson's disease.

  • 2.1 Mechanism of action ( pharmacodynamics )
  • 3.1 Patent

Clinical information

Areas of application (indications )

Istradefyllin leads to a reduction of the symptom occurring in the conventional treatment of Parkinson's dyskinesia. Currently, the drug is still in clinical trials.

Pharmacological properties

Mechanism of action ( pharmacodynamics )

Istradefyllin is an adenosine A2 receptor antagonist. He thus inhibits the excitatory signal transduction.

Other Information

Patent

  • EP 1054012
  • WO 9935147
  • CA 2315736
CAS registry number PubChem Active ingredient Parkinson's disease
420224
de